Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab vs Docetaxel in previously treated advanced NSCLC (CheckMate 078)
NCT02613507Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2015
- Primary completion
- Sep 2017
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of nivolumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Overall Survival at 22 months and Overall Survival Rate at 22 months. Started Dec 2015; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02613507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02613507.